Cancer Advisor

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: August 12, 2026 Important: This article is an evidence review, not a treatment protocol or medical advice. RESET-5, RESET-6 and related combinations are experimental concepts rather than established standards of cancer care. Ivermectin, mebendazole, niclosamide, celecoxib, metformin and other prescription medicines should not be started, combined, stopped or dose-adjusted for cancer without supervision from a qualified clinician. Experimental approaches should not replace surgery, radiation, chemotherapy, targeted therapy, immunotherapy or other evidence-based treatment when these are indicated. Abstract Background: Drug repurposing has attracted increasing interest in oncology because several inexpensive, already-approved medicines have demonstrated anticancer effects in laboratory models. A series of article...

Edited and Updated: June 2026  Caution to the Reader: This is a complex, evolving topic rooted in molecular biology and evolutionary dynamics. The material below has been distilled for clinical accessibility while preserving strict mechanistic accuracy. Key conceptual frameworks from the Care Oncology Clinic (COC) protocol and Thomas Seyfried’s press–pulse model are integrated throughout. Introduction Clinicians utilizing a metabolic framework often combine 4–5 repurposed prescription agents with 4–5 nutraceuticals. While this approach frequently yields 1–2 years of sustained, stable response, acquired resistance can emerge rapidly, turning stable disease into aggressive progression. When this occurs, critical clinical questions arise: How should the regimen be modified? Should mechanistically similar agents be cycled more frequently? Should dosing be intermittent rather than continuous? What ...

From “Undruggable” to One of the Most Important Targets in Cancer Medicine For decades, KRAS mutations were considered one of the most challenging problems in oncology. The protein was structurally smooth, biologically complex, and notoriously resistant to drug binding. It became known in medical literature as “undruggable.” That narrative changed dramatically in the early 2020s. Today, KRAS is no longer a scientific dead end—it is one of the most actively targeted oncogenic drivers in modern precision medicine. Multiple generations of KRAS inhibitors now exist, and treatment strategies are evolving from single-mutation targeting toward pan-RAS pathway control and combination therapy systems . However, despite major breakthroughs, KRAS-driven cancers remain difficult to cure. The reason is not a lack of drugs—but the adaptability of cancer biology itself. Update (May 2026): Daraxonrasib Pancreatic Cancer Drug : New RAS Inhibitor Doubles Survival in Phase 3 Trial This article provides a...

In a revealing post on X (formerly Twitter), whistleblower account @Jikkyleaks has shed light on four prominent universities that have quietly pursued patents and research on anti-parasitic medications—such as ivermectin, mebendazole, and fenbendazole—for treating various cancers. These drugs, long used to combat parasites in humans and animals, are now being explored for their potential anticancer properties.  The post, which credits AI assistant Grok for verifying the details, questions why this potentially game-changing information hasn't been more publicly disseminated. Drawing from the post and its sources, this article explores the universities involved, the science behind the drugs, and the broader implications. The Universities and Their Patent Pursuits According to the information compiled in the post, these institutions have been actively involved in patenting or researching these repurposed drugs. Here's a breakdown: University of British Columbia (UBC) The Universi...